Goldman Sachs Group Inc Sarepta Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$613 Billion
Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 477,066 shares of SRPT stock, worth $48.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

477,066

Previous 301,021 58.48%

Holding current value

$48.4 Million

Previous $37.6 Million 54.28%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$104.54 - $137.94 $18.4 Million - $24.3 Million	176,045 Added 58.48%	477,066 $58 Million
Q3 2024 Nov 14, 2024	SELL	$124.33 - $156.75 $17.2 Million - $21.7 Million	-138,556 Reduced 31.52%	301,021 $37.6 Million
Q2 2024 Aug 13, 2024	BUY	$113.33 - $163.85 $21.5 Million - $31.1 Million	189,530 Added 75.8%	439,577 $69.5 Million
Q1 2024 May 15, 2024	BUY	$93.7 - $141.53 $6.11 Million - $9.22 Million	65,177 Added 35.26%	250,047 $32.4 Million
Q4 2023 Feb 13, 2024	SELL	$67.31 - $124.76 $37.6 Million - $69.6 Million	-558,022 Reduced 75.11%	184,870 $17.8 Million
Q3 2023 May 14, 2024	BUY	$102.5 - $123.59 $57.2 Million - $69 Million	558,022 Added 301.85%	742,892 $90.1 Million
Q3 2023 Nov 14, 2023	SELL	$102.5 - $123.59 $23.2 Million - $28 Million	-226,396 Reduced 23.36%	742,892 $90.1 Million
Q2 2023 May 14, 2024	BUY	$106.4 - $157.19 $22.5 Million - $33.2 Million	211,216 Added 27.86%	969,288 $111 Million
Q2 2023 Aug 14, 2023	BUY	$106.4 - $157.19 $22.5 Million - $33.2 Million	211,216 Added 27.86%	969,288 $111 Million
Q1 2023 May 14, 2024	SELL	$117.53 - $155.99 $56.5 Million - $75 Million	-480,755 Reduced 38.81%	758,072 $104 Million
Q1 2023 May 11, 2023	SELL	$117.53 - $155.99 $56.5 Million - $75 Million	-480,755 Reduced 38.81%	758,072 $104 Million
Q4 2022 May 14, 2024	BUY	$100.86 - $132.13 $10.3 Million - $13.5 Million	102,134 Added 8.99%	1,238,827 $161 Million
Q4 2022 Feb 13, 2023	BUY	$100.86 - $132.13 $10.3 Million - $13.5 Million	102,134 Added 8.99%	1,238,827 $161 Million
Q3 2022 May 14, 2024	SELL	$75.71 - $119.24 $20.8 Million - $32.7 Million	-274,230 Reduced 19.44%	1,136,693 $126 Million
Q3 2022 Nov 10, 2022	SELL	$75.71 - $119.24 $20.8 Million - $32.7 Million	-274,230 Reduced 19.44%	1,136,693 $126 Million
Q2 2022 May 14, 2024	BUY	$62.69 - $88.44 $76.9 Million - $108 Million	1,226,053 Added 663.2%	1,410,923 $106 Million
Q2 2022 Aug 15, 2022	BUY	$62.69 - $88.44 $30.5 Million - $43.1 Million	486,867 Added 52.69%	1,410,923 $106 Million
Q1 2022 May 16, 2022	SELL	$63.15 - $90.42 $5.19 Million - $7.43 Million	-82,149 Reduced 8.16%	924,056 $72.2 Million
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $10.3 Million - $13.2 Million	133,210 Added 15.26%	1,006,205 $90.6 Million
Q3 2021 Nov 10, 2021	BUY	$65.97 - $92.48 $57.6 Million - $80.7 Million	872,995 New	872,995 $80.7 Million

Others Institutions Holding SRPT

# of Institutions

535

Shares Held

87.4M

Call Options Held

1.55M

Put Options Held

1.35M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $8.88B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Sarepta Therapeutics, Inc. Transaction History